Kathleen P. Gallagher Form 3 Avidity Biosciences / Kathleen P. Gallagher ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Gallagher Kathleen P.

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DR., SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/06/2025

3. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Program Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	34,965(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	04/25/2031	Common Stock	22,321	25.12	D
Stock Option (Right to Buy)	(3)	10/27/2031	Common Stock	1,001	22.56	D
Stock Option (Right to Buy)	(4)	01/19/2032	Common Stock	25,250	14.7	D
Stock Option (Right to Buy)	(5)	07/17/2032	Common Stock	40,550	16.65	D
Stock Option (Right to Buy)	(6)	01/19/2033	Common Stock	27,584	22.47	D
Stock Option (Right to Buy)	(3)	08/06/2033	Common Stock	1,000	8.82	D
Stock Option (Right to Buy)	(7)	08/19/2033	Common Stock	42,480	8.24	D
Stock Option (Right to Buy)	(8)	01/19/2034	Common Stock	13,520	10.16	D
Stock Option (Right to Buy)	(9)	08/29/2034	Common Stock	16,000	44	D

Explanation of Responses:

1. Includes restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 1,991 RSUs on each of the first four anniversaries of January 20, 2023; 6,125 RSUs on each of the first four anniversaries of January 20, 2024; and 625 RSUs on each of the first four anniversaries of August 30, 2024, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

2. This option was granted on April 26, 2021 and vests in equal installments of 2,029 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on April 26, 2025.

3. This option is fully vested and exercisable as of the date hereof.

4. This option was granted on January 20, 2022 and vests in equal installments of 1,383 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2026.

5. This option was granted on July 18, 2022 and vests in equal installments of 553 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026.

6. This option was granted on January 20, 2023 and vests in equal installments of 774 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.

7. This option was granted on August 20, 2023 and vests in equal installments of 885 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on August 20, 2027.

8. This option was granted on January 20, 2024 and vests in equal installments of 282 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.

9. This option was granted on August 30, 2024 and vests in equal installments of 333 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on August 30, 2028.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	01/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.